JU121606
Nehra A et al: DIAGNOSIS AND TREATMENT OF ERECTILE DYSFUNCTION FOR REDUCTION OF CARDIOVASCULAR RISK
Supplementary references
51. Gibbs, B. B., Brancati, F. L., Chen, H. et al.: Effect of improved fitness beyond weight
loss on cardiovascular risk factors in individuals with type 2 diabetes in the Look
AHEAD study. Eur J Prev Cardiol, 2012
52. Bacon, C. G., Mittleman, M. A., Kawachi, I. et al.: A prospective study of risk factors for
erectile dysfunction. J Urol, 176: 217, 2006
53. Andersen, I., Heitmann, B. L., Wagner, G.: Obesity and sexual dysfunction in younger
Danish men. J Sex Med, 5: 2053, 2008
54. Kalter-Leibovici, O., Wainstein, J., Ziv, A. et al.: Clinical, socioeconomic, and lifestyle
parameters associated with erectile dysfunction among diabetic men. Diabetes Care, 28:
1739, 2005
55. Cheng, J. Y., Ng, E. M.: Body mass index, physical activity and erectile dysfunction: an
U-shaped relationship from population-based study. Int J Obes (Lond), 31: 1571, 2007
56. Kratzik, C. W., Lackner, J. E., Mark, I. et al.: How much physical activity is needed to
maintain erectile function? Results of the Androx Vienna Municipality Study. Eur Urol,
55: 509, 2009
57. Feldman, H. A., Johannes, C. B., Derby, C. A. et al.: Erectile dysfunction and coronary
risk factors: prospective results from the Massachusetts male aging study. Prev Med, 30:
328, 2000
58. Derby, C. A., Mohr, B. A., Goldstein, I. et al.: Modifiable risk factors and erectile
dysfunction: can lifestyle changes modify risk? Urology, 56: 302, 2000
59. Rosen, R. C., Wing, R. R., Schneider, S. et al.: Erectile dysfunction in type 2 diabetic
men: relationship to exercise fitness and cardiovascular risk factors in the Look AHEAD
trial. J Sex Med, 6: 1414, 2009
60. Kupelian, V., Araujo, A. B., Chiu, G. R. et al.: Relative contributions of modifiable risk
factors to erectile dysfunction: results from the Boston Area Community Health (BACH)
Survey. Prev Med, 50: 19, 2010
61. Esposito, K., Giugliano, F., Di Palo, C. et al.: Effect of lifestyle changes on erectile
dysfunction in obese men: a randomized controlled trial. JAMA, 291: 2978, 2004
62. Esposito, K., Ciotola, M., Giugliano, F. et al.: Effects of intensive lifestyle changes on
erectile dysfunction in men. J Sex Med, 6: 243, 2009
63. Gupta, B. P., Murad, M. H., Clifton, M. M. et al.: The Effect of Lifestyle Modification
and Cardiovascular Risk Factor Reduction on Erectile Dysfunction: A Systematic Review
and Meta-analysis. Arch Intern Med, 2011
64. Maio, G., Saraeb, S., Marchiori, A.: Physical activity and PDE5 inhibitors in the
treatment of erectile dysfunction: results of a randomized controlled study. J Sex Med, 7:
2201, 2010
65. La Vignera, S., Condorelli, R., Vicari, E. et al.: Aerobic physical activity improves
endothelial function in the middle-aged patients with erectile dysfunction. Aging Male,
14: 265, 2011
66. Meldrum, D. R., Gambone, J. C., Morris, M. A. et al.: Lifestyle and metabolic
approaches to maximizing erectile and vascular health. Int J Impot Res, 24: 61, 2012
67. Kloner, R. A., Jackson, G., Hutter, A. M. et al.: Cardiovascular safety update of
Tadalafil: retrospective analysis of data from placebo-controlled and open-label clinical
trials of Tadalafil with as needed, three times-per-week or once-a-day dosing. Am J
Cardiol, 97: 1778, 2006
68. Giuliano, F., Jackson, G., Montorsi, F. et al.: Safety of sildenafil citrate: review of 67
double-blind placebo-controlled trials and the postmarketing safety database. Int J Clin
Pract, 64: 240, 2010
69. Revatio®. In: sildenafil citrate. New York, NY: Pfizer Inc, 2009
70. Adcirca. In: Tadalafil. Indianapolis, IN: Eli Lilly and Company, 2011
71. Roumeguere, T., Wespes, E., Carpentier, Y. et al.: Erectile dysfunction is associated with
a high prevalence of hyperlipidemia and coronary heart disease risk. Eur Urol, 44: 355,
2003
72. Solomon, H., Samarasinghe, Y. P., Feher, M. D. et al.: Erectile dysfunction and statin
treatment in high cardiovascular risk patients. Int J Clin Pract, 60: 141, 2006
73. Do, C., Huyghe, E., Lapeyre-Mestre, M. et al.: Statins and erectile dysfunction: results of
a case/non-case study using the French Pharmacovigilance System Database. Drug Saf,
32: 591, 2009
74. Stanworth, R. D., Kapoor, D., Channer, K. S. et al.: Statin therapy is associated with
lower total but not bioavailable or free testosterone in men with type 2 diabetes. Diabetes
Care, 32: 541, 2009
75. Corona, G., Boddi, V., Balercia, G. et al.: The effect of statin therapy on testosterone
levels in subjects consulting for erectile dysfunction. J Sex Med, 7: 1547, 2010
76. Mastalir, E. T., Carvalhal, G. F., Portal, V. L.: The effect of simvastatin in penile
erection: a randomized, double-blind, placebo-controlled clinical trial (Simvastatin
treatment for erectile dysfunction-STED TRIAL). Int J Impot Res, 23: 242, 2011
77. Saltzman, E. A., Guay, A. T., Jacobson, J.: Improvement in erectile function in men with
organic erectile dysfunction by correction of elevated cholesterol levels: a clinical
observation. J Urol, 172: 255, 2004
78. Gokkaya, S. C., Ozden, C., LeventOzdal, O. et al.: Effect of correcting serum cholesterol
levels on erectile function in patients with vasculogenic erectile dysfunction. Scand J
Urol Nephrol, 42: 437, 2008
79. Dadkhah, F., Safarinejad, M. R., Asgari, M. A. et al.: Atorvastatin improves the response
to sildenafil in hypercholesterolemic men with erectile dysfunction not initially
responsive to sildenafil. Int J Impot Res, 22: 51, 2010
80. Miner, M., Billups, K. L.: Erectile dysfunction and dyslipidemia: relevance and role of
phosphodiesterase type-5 inhibitors and statins. J Sex Med, 5: 1066, 2008
81. Haendeler, J., Hoffmann, J., Zeiher, A. M. et al.: Antioxidant effects of statins via Snitrosylation
and activation of thioredoxin in endothelial cells: a novel vasculoprotective
function of statins. Circulation, 110: 856, 2004
82. Ascer, E., Bertolami, M. C., Venturinelli, M. L. et al.: Atorvastatin reduces
proinflammatory markers in hypercholesterolemic patients. Atherosclerosis, 177: 161,
2004
83. Bruckert, E., Giral, P., Heshmati, H. M. et al.: Men treated with hypolipidaemic drugs
complain more frequently of erectile dysfunction. J Clin Pharm Ther, 21: 89, 1996
84. Burchardt, M., Burchardt, T., Baer, L. et al.: Hypertension is associated with severe
erectile dysfunction. J Urol, 164: 1188, 2000
85. Giuliano, F. A., Leriche, A., Jaudinot, E. O. et al.: Prevalence of erectile dysfunction
among 7689 patients with diabetes or hypertension, or both. Urology, 64: 1196, 2004
86. Bener, A., Al-Ansari, A., Afifi, M. et al.: Erectile dysfunction among hypertensive men
in a rapidly developing country. Indian J Urol, 23: 109, 2007
87. Sun, P., Swindle, R.: Are men with erectile dysfunction more likely to have hypertension
than men without erectile dysfunction? A naturalistic national cohort study. J Urol, 174:
244, 2005
88. Seftel, A. D., Sun, P., Swindle, R.: The prevalence of hypertension, hyperlipidemia,
diabetes mellitus and depression in men with erectile dysfunction. J Urol, 171: 2341,
2004
89. Llisterri, J. L., Lozano Vidal, J. V., Aznar Vicente, J. et al.: Sexual dysfunction in
hypertensive patients treated with losartan. Am J Med Sci, 321: 336, 2001
90. Baumhakel, M., Schlimmer, N., Kratz, M. et al.: Cardiovascular risk, drugs and erectile
function - a systematic analysis. Int J Clin Pract, 65: 289, 2011
91. Fogari, R., Zoppi, A., Poletti, L. et al.: Sexual activity in hypertensive men treated with
valsartan or carvedilol: a crossover study. Am J Hypertens, 14: 27, 2001
92. Doumas, M., Tsakiris, A., Douma, S. et al.: Beneficial effects of switching from betablockers
to nebivolol on the erectile function of hypertensive patients. Asian J Androl, 8:
177, 2006
93. Boydak, B., Nalbantgil, S., Fici, F. et al.: A Randomised Comparison of the Effects of
Nebivolol and Atenolol with and without Chlorthalidone on the Sexual Function of
Hypertensive Men. Clin Drug Investig, 25: 409, 2005
94. Brixius, K., Middeke, M., Lichtenthal, A. et al.: Nitric oxide, erectile dysfunction and
beta-blocker treatment (MR NOED study): benefit of nebivolol versus metoprolol in
hypertensive men. Clin Exp Pharmacol Physiol, 34: 327, 2007
95. Grimm, R. H., Jr., Grandits, G. A., Prineas, R. J. et al.: Long-term effects on sexual
function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive
men and women. Treatment of Mild Hypertension Study (TOMHS). Hypertension, 29: 8,
1997
96. Baumhakel, M., Schlimmer, N., Bohm, M.: Effect of irbesartan on erectile function in
patients with hypertension and metabolic syndrome. Int J Impot Res, 20: 493, 2008
97. Dusing, R.: Effect of the angiotensin II antagonist valsartan on sexual function in
hypertensive men. Blood Press Suppl, 2: 29, 2003
98. Bank, A. J., Kelly, A. S., Kaiser, D. R. et al.: The effects of quinapril and atorvastatin on
the responsiveness to sildenafil in men with erectile dysfunction. Vasc Med, 11: 251,
2006
99. Kifor, I., Williams, G. H., Vickers, M. A. et al.: Tissue angiotensin II as a modulator of
erectile function. I. Angiotensin peptide content, secretion and effects in the corpus
cavernosum. J Urol, 157: 1920, 1997
100. Flammer, A. J., Hermann, F., Wiesli, P. et al.: Effect of losartan, compared with atenolol,
on endothelial function and oxidative stress in patients with type 2 diabetes and
hypertension. J Hypertens, 25: 785, 2007
101. Cordero, A., Bertomeu-Martinez, V., Mazon, P. et al.: Erectile dysfunction in high-risk
hypertensive patients treated with beta-blockade agents. Cardiovasc Ther, 28: 15, 2010
102. Bolona, E. R., Uraga, M. V., Haddad, R. M. et al.: Testosterone use in men with sexual
dysfunction: a systematic review and meta-analysis of randomized placebo-controlled
trials. Mayo Clin Proc, 82: 20, 2007
103. Buvat, J., Montorsi, F., Maggi, M. et al.: Hypogonadal men nonresponders to the PDE5
inhibitor tadalafil benefit from normalization of testosterone levels with a 1%
hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST
study). J Sex Med, 8: 284, 2011
104. Hackett, G.: Long acting testosterone undecanoate improved ageing male symptom
scores but not depression versus placebo in a hypogonadal population with type 2
diabetes. In: 14th European Society of Sexual Medicine Congress. Milan, Italy, 2011